Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology

被引:33
|
作者
Hoyt, Clifford C. [1 ]
机构
[1] Akoya Biosci Inc, Malborough, MA USA
关键词
Predictive biomarkers; multiplex immunofluorescence; multispectral imaging; immuno-oncology; clinical workflow; image analysis; automated staining; spatial biology; LUNG-CANCER; EXPRESSION; ASSAY; IMMUNOHISTOCHEMISTRY; REPRODUCIBILITY; ASSOCIATION; NSCLC;
D O I
10.3389/fmolb.2021.674747
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As immuno-oncology (I/O) emerges as an effective approach in the fight against cancer, multispectral imaging of multiplex immunofluorescence (mIF) is maturing as an analytical platform. The timing is fortuitous. Due to health economic considerations surrounding the use of I/O, there is an urgent need for tests that accurately predict response to the growing list of available therapies. Multispectral mIF provides several advantages over other biomarker modalities by enabling deeper interrogation of the intricate biology within the tumor microenvironment, including detection of cell-to-cell spatial interactions that correlate with clinical outcomes. It also provides a practical path for generating reliable and reproducible results in a clinically suitable, high-throughput workflow. In this article, we (1) describe the principles behind multispectral mIF; (2) provide advice and recommendations on assay development and optimization and highlight characteristics of a well-performing assay; and (3) discuss the requirements for translating this approach into clinical practice.
引用
收藏
页数:14
相关论文
共 48 条
  • [21] Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
    Noelle, Randolph J.
    Lines, J. Louise
    Lewis, Lionel D.
    Martell, Robert E.
    Guillaudeux, Thierry
    Lee, Sam W.
    Mahoney, Kathleen M.
    Vesely, Matthew D.
    Boyd-Kirkup, Jerome
    Nambiar, Dhanya K.
    Scott, Andrew M.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [22] Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer
    Jahangir, Chowdhury Arif
    Page, David B.
    Broeckx, Glenn
    Gonzalez, Claudia A.
    Burke, Caoimbhe
    Murphy, Clodagh
    Reis-Filho, Jorge S.
    Ly, Amy
    Harms, Paul W.
    Gupta, Rajarsi R.
    Vieth, Michael
    Hida, Akira, I
    Kahila, Mohamed
    Kos, Zuzana
    van Diest, Paul J.
    Verbandt, Sara
    Thagaard, Jeppe
    Khiroya, Reena
    Abduljabbar, Khalid
    Haab, Gabriela Acosta
    Acs, Balazs
    Adams, Sylvia
    Almeida, Jonas S.
    Alvarado-Cabrero, Isabel
    Azmoudeh-Ardalan, Farid
    Badve, Sunil
    Baharun, Nurkhairul Bariyah
    Bellolio, Enrique R.
    Bheemaraju, Vydehi
    Blenman, Kim R. M.
    Fujimoto, Luciana Botinelly Mendonca
    Burgues, Octavio
    Chardas, Alexandros
    Cheang, Maggie Chon U.
    Ciompi, Francesco
    Cooper, Lee A. D.
    Coosemans, An
    Corredor, German
    Portela, Flavio Luis Dantas
    Deman, Frederik
    Demaria, Sandra
    Dudgeon, Sarah N.
    Elghazawy, Mahmoud
    Fernandez-Martin, Claudio
    Fineberg, Susan
    Fox, Stephen B.
    Giltnane, Jennifer M.
    Gnjatic, Sacha
    Gonzalez-Ericsson, Paula, I
    Grigoriadis, Anita
    JOURNAL OF PATHOLOGY, 2024, 262 (03) : 271 - 288
  • [23] Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue
    Parra, Edwin Roger
    Ferrufino-Schmidt, Maria C.
    Tamegnon, Auriole
    Zhang, Jiexin
    Solis, Luisa
    Jiang, Mei
    Ibarguen, Heladio
    Haymaker, Cara
    Lee, J. Jack
    Bernatchez, Chantale
    Wistuba, Ignacio Ivan
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [24] Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy
    Yan Ji
    Sherwin K. B. Sy
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 273 - 293
  • [25] Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy
    Ji, Yan
    Sy, Sherwin K. B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 273 - 293
  • [26] A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects
    He, Pei
    Su, Zheng
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2015, 1 : 28 - 31
  • [27] A pan-cancer analysis of MARCH8: molecular characteristics, clinical relevance, and immuno-oncology features
    Quan, Zihan
    Fan, Songqing
    Zheng, Hongmei
    Ning, Yue
    Yang, Yang
    CANCER BIOLOGY & THERAPY, 2025, 26 (01)
  • [28] Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets
    Rachev, Boris
    Wilking, Nils
    Kobelt, Gisela
    Spandonaro, Federico
    Rajer, Mirjana
    Roediger, Alexander
    Normand, Raphael
    Zielinski, Christoph
    JOURNAL OF CANCER POLICY, 2021, 28
  • [29] Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
    Cavalieri, Stefano
    Rivoltini, Licia
    Bergamini, Cristiana
    Locati, Laura D.
    Licitra, Lisa
    Bossi, Paolo
    CANCER TREATMENT REVIEWS, 2018, 65 : 78 - 86
  • [30] Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy
    Liu, Rachael
    Lin, Jianchang
    Li, Pin
    CONTEMPORARY CLINICAL TRIALS, 2020, 96